Risk of ipsilateral breast event after surgical excision increases over time
the ONA take:
Women with ductal carcinoma in situ (DCIS) who undergo surgical resection without radiation have an increased risk of developing recurrence of DCIS or invasive disease, and that risk increases over time.
A prospective clinical trial sought to determine the 12-year risk of an ipsilateral breast event (IBE) in women with DCIS of the breast treated with lumpectomy without radiation. The results were presented in part at the San Antonio Breast Cancer Symposium.
Study participants were enrolled into two cohorts, not randomly assigned. Cohort 1 was 561 patients with low- or intermediate grade DCIS, tumor size 2.5 cm or smaller. Cohort 2 was 104 patients with high-grade DCIS, tumor size 1 cm or smaller.
Patients underwent excision of the DCIS tumor with a minimum negative margin width of at least 3 mm, and 30% of the patients received tamoxifen (not randomly assigned). An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast. Patients were followed for a median of 12.3 years. There were 99 IBEs, of which 51 were invasive.
Results show that 12-year rates of developing an IBE was 14.4% for cohort 1 and 24.6% for cohort 2; 12-year rates for developing an invasive IBE were 7.5% in cohort 1 and 13.4% in cohort 2. Study cohort and tumor size were significantly associated with risk for IBE.
Women with ductal carcinoma in situ who undergo surgical resection without radiation have an increased risk of developing recurrence.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|